|
|
| (2 intermediate revisions by 2 users not shown) |
| Line 1: |
Line 1: |
| {{Drugbox
| | #REDIRECT [[Temsirolimus]] |
| | IUPAC_name =
| |
| | image = Temsirolimus.png
| |
| | CAS_number = 162635-04-3
| |
| | ATC_prefix =
| |
| | ATC_suffix =
| |
| | PubChem = 6918289
| |
| | DrugBank =
| |
| | chemical_formula =
| |
| | molecular_weight =
| |
| | bioavailability =
| |
| | protein_bound =
| |
| | metabolism =
| |
| | elimination_half-life =
| |
| | excretion =
| |
| | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| |
| | pregnancy_US = <!-- A / B / C / D / X -->
| |
| | pregnancy_category=
| |
| | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| |
| | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| |
| | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| |
| | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| |
| | legal_status =
| |
| | routes_of_administration =
| |
| }}
| |
| {{SI}}
| |
| {{EH}}
| |
| | |
| '''Temsirolimus''' is an intravenous drug for the treatment of [[renal cell carcinoma]] (RCC), developed by [[Wyeth]] Pharmaceuticals and approved by the [[FDA]] in late May 2007.<ref>[http://www.fda.gov/bbs/topics/NEWS/2007/NEW01644.html FDA.gov]</ref> It is a derivative of the [[macrolide]] [[sirolimus]].
| |
| | |
| The drug is promising for RCC patients. A phase III clinical study of the drug showed a 49 percent increase in patients' median overall survival time (10.9 months).<ref>[http://www.drugs.com/nda/torisel_061006.html Drugs.com]</ref> The drug was administered to patients who had received no prior systemic therapy; however, this study only included patients with a poor prognosis. The benefits of temsirolimus in patients with favorable or intermediate prognostic factors remains to be elucidated.
| |
| | |
| | |
| | |
| [[Category:Macrolide antibiotics]]
| |
| {{SIB}}
| |
| {{WH}}
| |
| {{WikiDoc Sources}}
| |